STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amylyx Pharmaceuticals is awaiting Phase 3 LUCIDITY trial results for avexitide, aimed at post-bariatric hypoglycemia, described as a rare metabolic condition causing severe drops in blood sugar
- Biogen will present detailed Phase 2 data on its Alzheimer's treatment diranersen on July 14 at the Alzheimer's Association International Conference, after first announcing top-line results in May
- Diranersen is designed to target the tau protein, distinguishing it from more common amyloid-targeting Alzheimer's approaches
- The full scorecard flags 15 distinct stock-moving events for the third quarter, presented as STAT's recurring "biotech scorecard" ledger
- Only the Amylyx and Biogen entries are visible in the free preview; details on the other 13 events sit behind a STAT+ subscription wall
Why it matters: For biotech investors, the scorecard distills which Q3 clinical readouts could trigger outsized stock moves — two named events already on the calendar include Amylyx's LUCIDITY Phase 3 readout on avexitide and Biogen's July 14 diranersen data drop at the Alzheimer's Association conference, both directly tied to named drugs with specific trial milestones.
Ask SkimNews
